The importance of EGFR as a biomarker in molecular apocrine breast cancer

Liu, Xiaozhen; Feng, Changyun; Liu, Junjun; Liu, Jian; Li, Congying; Xu, Cong; Niu, Yun

doi:10.1016/j.humpath.2018.01.016

Cited by 19 publications

(17 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If the cut-off value of AR is ≥1%, the difference between the clinicopathological parameters of AR is similar to the AR-positive nuclear staining tumour cells ≥ 10% (except the difference between AR expression and patient's age is inconsistent). with the AR, this is consistent with our previous research results [18]. Compared with other subtypes of carcinoma, the coloration intensity of AR is much stronger, and there were few cases of heterogeneous coloration.…”

Section: The Relationship Between Ar Expression and Clinicopathologicsupporting

confidence: 92%

Expression features of androgen receptor in special subtypes of breast cancer

Xiang

Liu

Cao

et al. 2019

Preprint

Self Cite

View full text Add to dashboard Cite

Purpose The important role of the androgen receptor (AR) in invasive carcinoma of no specific type (NST) has been increasingly recognised. However, only a few studies have been reported in special subtypes of breast cancer. Thus, we aim to investigate the AR expression and its expression features in special subtypes of breast cancer. Methods This study collected clinicopathological data of 718 special subtypes of breast cancer from Tianjin Medical University Cancer Institute and Hospital. Immunohistochemical staining of AR and other biomarkers was performed. Results If the threshold of AR is ≥ 1%, the positive rate of AR in specific subtypes of breast cancer is 77.9% (559/718) of cases. Compared with the threshold of AR is ≥ 10%, the positive percentage of AR in each subtype of breast cancer increases about 10%. The positive expression rate of AR in carcinomas with apocrine differentiation is highest, and the coloration intensity is much stronger than that of other subtypes. The positive expression rate of AR is lowest in metaplastic carcinomas, almost negative; the positive expression rate of AR in invasive lobular carcinomas (ILCs), invasive micropapillary carcinomas (IMPCs), invasive papillary carcinomas (IPCs), and is mucinous carcinomas about 70.0%–80.0%. Conclusions The expression features of AR in special subtypes of breast cancer vary in different subtypes, and to some extent, AR may be a useful biomarker for clinical diagnosis. Routine testing of AR has a certain guiding significance for clinical work. In addition, AR is expected to treat carcinomas with apocrine differentiation as a target.

show abstract

Section: The Relationship Between Ar Expression and Clinicopathologicsupporting

confidence: 92%

Expression features of androgen receptor in special subtypes of breast cancer

Xiang

Liu

Cao

et al. 2019

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…Table VI represents a review of studies concerning the survival of patients with apocrine carcinoma. Usually the studies investigated the differences between apocrine/ molecular apocrine carcinomas and other breast carcinoma groups (defined by the authors; Table VI) [7,8,10,11,12,17,20,23,24,25,30,31]. In our study the probability of 10-years overall survival was 66.2% and disease-free survival was 62.7%.…”

Section: Discussionmentioning

confidence: 69%

“…The relationship between ER/PgR lack of expression and EGFR expression was reported not only in apocrine carcinomas [10,18] but also in other breast carcinoma subtypes [29].…”

Section: Discussionmentioning

confidence: 98%

“…Based on morphological features, another term was introduced: pure apocrine carcinoma [7]; however, some authors define this category as tumours characterised by apocrine differentiation with AR+/ER-/ PgR-immunohistochemical (IHC) profile [8,9]. These two definitions are overlapping because some authors use immunochemistry phenotype AR+/ ER-/PgR-to define molecular apocrine breast carcinoma [10,11].…”

Section: Introductionmentioning

confidence: 99%

“…The clinicopathological and biological characteristics of apocrine carcinoma are intensively studied; however, comparing data might be a problem because some authors investigate differently characterized groups: apocrine carcinoma/pure apocrine carcinoma (based on only morphological feature) [4,8,12,13,14,15,16,17,18] or with additional AR+/ER-/PgR-IHC profile [8,9,19], molecular apocrine [10,20,21,22,23,24], or the subgroup of apocrine carcinomas in triple-negative breast carcinoma subtype [25]. The expression of a number of biological markers have been investigated, mainly: AR, ER, and PgR [4,8,9,11,13,16,17,18,19,20,24,25] as well as epidermal growth factor receptor 1 and/or 2 (EGFR, HER2) [8,9,10,11,13,15,16,17,18,19,20,22,23,25], proliferation rate based on assessment of Ki-67 expression…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

High Ki-67 expression is a marker of poor survival in apocrine breast carcinoma

Wysocka

Adamczyk

Kruczak

et al. 2020

pjp

View full text Add to dashboard Cite

Apocrine carcinoma is a very rare type of breast cancer, which represents 0.5-4% of all breast cancers. The aim of the study was to analyze biological and clinical features of apocrine carcinoma and their influence on patients survival. The studied group consists of 57 patients, who underwent treatment between 1987 and 2010. Expression of ER, PgR, HER2, AR, GCDFP-15, EGFR, CK 5/6, CK 8/18 and Ki-67 was assessed immunohistochemically on formalin-fixed paraffin-embedded tissue sections. Presence of emboli and extent of lymphocyte infiltration were assessed on haematoxylin-eosin-stained slides. In the investigated group, 16 cases were ER/PgR positive and 49 were AR-positive. ER/PgR-negative tumours were often characterised by CK5/6 and EGFR positivity. The presence of AR was related to HER-2 and GCDFP-15 expression and tumours with expression of CK5/6 were more likely be EGFR positive and had higher Ki-67 LI. Higher probability of 10-years OS and DFS was observed in patients with tumours characterized by Ki-67 LI < 20% (p = 0.036 and p = 0.009, respectively). Favourable trend in OS was noted for patients with smaller tumours (p = 0.053), without lymph node metastases (p = 0.074) and without EGFR expression (p = 0.060). In apocrine breast carcinoma expression of Ki-67 is one of the most important factors influencing patients' survival.

show abstract

Prognosis in triple‐negative apocrine carcinomas of the breast: A population‐based study

Peng

et al. 2019

Cancer Medicine

View full text Add to dashboard Cite

Background Triple‐negative apocrine carcinoma (TNAC) of the breast is a very rare type of breast cancer. Furthermore, the clinicopathological features, prognosis, and potential impact of treatment strategies in TNAC remain unclear. Methods Data from the Surveillance, Epidemiology, and End Results (SEER) program were used to identify breast cancer patients diagnosed between 2010 and 2016 with TNAC and triple‐negative breast cancer (TNBC, IDC [invasive ductal carcinoma], NOS [not otherwise specified]). Chi‐squared tests were used to examine the categorical variables between the two groups. Overall survival (OS) of TNAC and TNBC was assessed by Kaplan‐Meier analyses and Cox regression. Breast cancer‐specific survival (BCSS) was evaluated by Nelson‐Aalen analyses and competing risk regression. Results We identified 31 362 patients from the SEER database, including 366 patients with TNAC and 30 996 patients with TNBC. TNAC was correlated with older age, lower T stage and lower tumor grade. Patients with TNAC had better OS compared with TNBC patients; the 5‐year OS rates were 82.2% vs 73.5% (P < .001). The breast cancer‐related death rate was significantly lower in patients with TNAC than in patients with TNBC, with a 5‐year cumulative incidence of 9.1% vs 22.9% (P < .001). Chemotherapy was significantly associated with improved OS in TNAC patients, but radiotherapy was not associated with OS in TNAC patients. In the multivariable Cox regression, TNAC was still associated with improved OS (HR [hazard ratio], 0.61; 95% CI [confidence interval] 0.45‐0.83; P = .002). In the multivariable competing risk regression, the significantly higher BCSS in patients with TNAC compared patients with TNBC remained (subdistribution HR [SHR], 0.42; 95% CI, 0.27‐0.64; P < .001). Conclusion Patients with TNAC had a better prognosis than patients with TNBC, and chemotherapy was associated with survival advantages in TNAC patients.

show abstract

The importance of EGFR as a biomarker in molecular apocrine breast cancer

Cited by 19 publications

References 24 publications

Expression features of androgen receptor in special subtypes of breast cancer

Expression features of androgen receptor in special subtypes of breast cancer

High Ki-67 expression is a marker of poor survival in apocrine breast carcinoma

Prognosis in triple‐negative apocrine carcinomas of the breast: A population‐based study

Contact Info

Product

Resources

About